Bryan Wahl, M.D., J.D., is the General Counsel at Tarsus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in eye care and other therapeutic areas. Holding both a medical degree from the University of California, San Francisco, School of Medicine and a law degree from the University of California, Berkeley School of Law, Dr. Wahl combines deep clinical knowledge with rigorous legal expertise. His career spans over two decades in the life sciences industry, where he has advised on complex regulatory, transactional, and compliance matters for innovative biotech and pharmaceutical firms. Before joining Tarsus in 2022, Bryan served as Vice President, Legal at a prominent ophthalmology-focused company, where he led legal teams through multiple product launches, FDA approvals, and strategic partnerships. His achievements include orchestrating high-value licensing agreements exceeding $500 million, successfully litigating intellectual property disputes that protected critical pipeline assets, and guiding corporate restructurings during periods of rapid growth. Earlier roles at global law firms and Big Pharma companies honed his skills in healthcare mergers and acquisitions, antitrust issues, and international regulatory strategy. At Tarsus, Dr. Wahl oversees all legal functions, including corporate governance, intellectual property protection, and risk management, playing a key role in advancing the company's lead candidate, XDEMVY™ (lotilaner ophthalmic solution, 0.25%), the first FDA-approved treatment for Demodex blepharitis. His strategic counsel supports Tarsus's expansion into new indications and markets, ensuring robust compliance amid evolving industry regulations while fostering innovation in underserved medical areas.